<DOC>
	<DOCNO>NCT01991379</DOCNO>
	<brief_summary>The purpose study evaluate effect , good and/or bad , MEK162 imatinib patient Gastrointestinal Stromal Tumor ( GIST ) .</brief_summary>
	<brief_title>MEK162 Combination With Imatinib Mesylate Patients With Untreated Advanced Gastrointestinal Stromal Tumor ( GIST )</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients must pathologically confirm GIST . In Phase Ib portion , must locally advance metastatic GIST progress imatinib . In Phase II portion , patient must newly diagnose treatment naïve , adjuvant imatinib therapy least 3 month . Patients newly diagnose GIST imatinib 4 week prior sign consent allow enroll order expedite accrual . Patients must least 18 year age . Disease must measurable RECIST 1.1 . ECOG Performance Status 0 1 . Adequate renal , hepatic , hematologic function follow : Serum Creatinine ≤ 1.5 mg/dL , Total Serum Bilirubin ≤ 1.5 x upper limit normal ( ULN ) , Serum AST ( SGOT ) and/or ALT ( SGPT ) ≤ 2.5 x ULN ( ≤ 5.0 x ULN consider due tumor ) ANC ≥ 1500/mm3 , Platelets ≥ 100,000/mm3 , hemoglobin ≥ 10g/dL . Patients childbearing potential must negative serum pregnancy test within 14 day treatment . Patients must agree use reliable barrier method birth control 3 month follow last dose study drug . Patient must adequate cardiac function ( left ventricular ejection fraction ( LVEF ) ≥50 % determine multigated acquisition ( MUGA ) scan echocardiogram ; QTc interval≤480 m . Patient must able take oral medication . Patients must sign informed consent document . In phase II portion study , patient previously treat systemic therapy GIST permit enroll , exception adjuvant imatinib systemic therapy exposure imatinib within 4 week sign consent . Patients severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . Patients know brain metastasis . Patients know chronic liver disease ( i.e. , cirrhosis ) Known positive serology HIV , active Hepatitis B , and/or active Hepatitis C infection . Other active malignancy ( malignancy , investigator determines unlikely interfere treatment safety analysis ) . Patients history current evidence Central Serous Retinopathy ( CSR ) retinal vein occlusion ( RVO ) predispose factor CSR RVO ( i.e . uncontrolled glaucoma ocular hypertension , uncontrolled diabetes mellitus , hyperviscosity hypercoagulability syndrome ) . History retinal degenerative disease . History Gilbert 's syndrome . Patients clinically significant cardiovascular disease , include follow : 1 ) History acute coronary syndrome include myocardial infarction , unstable angina , CABG , coronary angioplasty stenting &lt; 6 month prior screen ; 2 ) symptomatic chronic heart failure ( New York Heart Association Criteria , Class IIIV ) ; 3 ) evidence clinically significant cardiac arrhythmia and/or conduction abnormality &lt; 6 month prior screen except atrial fibrillation ( AF ) paroxysmal supraventricular tachycardia ( PSVT ) . Uncontrolled arterial hypertension despite appropriate medical therapy . Patients neuromuscular disorder associate elevated creatinine phosphokinase ( i.e . inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) . Impairment gastrointestinal function gastrointestinal disease ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) . Prior therapy MEK inhibitor . Patients major surgery within 3 week prior study entry recover side effect procedure . Women pregnant lactating . Sexually active male unless use condom intercourse take drug 15 day stop treatment father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid . Patients significant history noncompliance medical regimen inability grant reliable informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MEK162</keyword>
	<keyword>Imatinib</keyword>
	<keyword>13-162</keyword>
</DOC>